Trial · NCT00858403
Dasatinib in Advanced Non-small Cell Lung Cancer (NSCL) With Ex Vivo and In Vivo Assessment of Tumor Target Modulation
NCT00858403, Phase 2, Terminated, H. Lee Moffitt Cancer Center and Research Institute; results first posted 2011-09-07
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Dasatinib in Advanced Non-small Cell Lung Cancer (NSCL) With Ex Vivo and In Vivo Assessment of Tumor Target Modulation. Trials, record NCT00858403. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00858403
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Dasatinib in Advanced Non-small Cell Lung Cancer (NSCL) With Ex Vivo and In Vivo Assessment of Tumor Target Modulation
- NCT number
- NCT00858403
- Status
- Terminated
- Phases
- Phase 2
- Enrollment
- 7 participants, actual
- Lead sponsor
- H. Lee Moffitt Cancer Center and Research Institute
- Conditions
- Lung Cancer
- Interventions
- Dasatinib
- First posted
- 2009-03-09
- Last updated
- 2014-01-15
- Results first posted
- 2011-09-07
- Limitations and caveats
- The low accrual of 7 participants prevented us from completing the planned analysis. Target accrual was 40.
Source ClinicalTrials.gov
Registered outcomes7
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Number of Participant Progressors vs. Non-progressors With Tumor Response | 1 year, 4 months | We planned to assess whether the extent of inhibition of extracellular signal-regulated protein kinase (ERK) phosphorylation in lung cancer cells exposed ex vivo to dasatinib significantly differed between patients categorized as progressors or non-progressors through standard Response Evaluation Criteria In Solid Tumors (RECIST) |
| Secondary | Number of Participants With Response to Dasatinib | 1 year, 4 months | We planned to estimate the single agent response rate to dasatinib in this patient population |
| Secondary | Number of Participants With Progression Free Survival (PFS) at 6 Months | 1 year, 4 months | We planned to estimate the 6 month progression free survival rate of dasatinib in this patient population. |
| Secondary | Number of Participants With Serious Adverse Events (SAEs) | 1 year, 4 months | We evaluated toxicity of dasatinib in this patient population. |
| Secondary | Number of Participant Progressors vs. Non-Progressors With Inhibition Response | 1 year, 4 months | We planned to assess whether the extent of inhibition of proto-oncogene tyrosine-protein kinase (SRC) and protein kinase B (Akt) phosphorylation in lung cancer cells exposed ex vivo and in vivo to dasatinib significantly differs between patients categorized as progressors or non-progressors through standard RECIST criteria. |
| Secondary | Correlation Between Extent of Inhibition and Concentration of Dasatinib | 1 year, 4 months | We planned to explore whether the extent of inhibition of ERK, SRC and Akt phosphorylation in lung cancer cells exposed ex vivo to dasatinib will correlate with the drug concentration of dasatinib. |
| Secondary | Correlation Between Mutation and Inhibition and to Disease Control Rate and Response | 1 year, 4 months | To analyze Kras and epidermal growth factor receptor (EGFR) mutation and their correlation to the ERK pathway inhibition and to disease control rate and response. |
Source ClinicalTrials.gov
Outcomes7
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Number of Participant Progressors vs. Non-progressors With Tumor Response | 1 year, 4 months | The low accrual of 7 participants prevented us from completing the planned analysis. Target accrual was 40. | ||
| SECONDARY | Number of Participants With Response to Dasatinib | 1 year, 4 months | The low accrual of 7 participants prevented us from completing the planned analysis. Target accrual was 40. | ||
| SECONDARY | Number of Participants With Progression Free Survival (PFS) at 6 Months | 1 year, 4 months | We were able to assess 4 of the 7 participants at 6 months. | Participants | NUMBER |
| SECONDARY | Number of Participants With Serious Adverse Events (SAEs) | 1 year, 4 months | Participants | NUMBER | |
| SECONDARY | Number of Participant Progressors vs. Non-Progressors With Inhibition Response | 1 year, 4 months | The low accrual of 7 participants prevented us from completing the planned analysis. Target accrual was 40. | ||
| SECONDARY | Correlation Between Extent of Inhibition and Concentration of Dasatinib | 1 year, 4 months | The low accrual of 7 participants prevented us from completing the planned analysis. Target accrual was 40. | ||
| SECONDARY | Correlation Between Mutation and Inhibition and to Disease Control Rate and Response | 1 year, 4 months | The low accrual of 7 participants prevented us from completing the planned analysis. Target accrual was 40. |
Source ClinicalTrials.gov
Results by group2
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number of Participants With Progression Free Survival (PFS) at 6 Months | Treatment With Dasatinib | 1 | Participants | ||
| Number of Participants With Serious Adverse Events (SAEs) | Treatment With Dasatinib | 3 | Participants |
Source ClinicalTrials.gov
Participant flow3
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Treatment With Dasatinib | 7 | |
| Overall Study | COMPLETED | Treatment With Dasatinib | 2 | |
| Overall Study | NOT COMPLETED | Treatment With Dasatinib | 5 |
Source ClinicalTrials.gov
Adverse events40
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Abdomen Pain | General disorders | Treatment With Dasatinib | 1 | 7 | 1 |
| other | Anorexia | Metabolism and nutrition disorders | Treatment With Dasatinib | 1 | 7 | 1 |
| other | Anorexia | Metabolism and nutrition disorders | Treatment With Dasatinib | 1 | 7 | 1 |
| other | Back Pain | General disorders | Treatment With Dasatinib | 1 | 7 | 1 |
| other | Blurred Vision | Eye disorders | Treatment With Dasatinib | 1 | 7 | 1 |
| other | Constipation | Gastrointestinal disorders | Treatment With Dasatinib | 1 | 7 | 1 |
| other | Cough | Respiratory, thoracic and mediastinal disorders | Treatment With Dasatinib | 1 | 7 | 1 |
| other | Cough | Respiratory, thoracic and mediastinal disorders | Treatment With Dasatinib | 1 | 7 | 1 |
| other | Creatinine | Renal and urinary disorders | Treatment With Dasatinib | 1 | 7 | 1 |
| other | Dehydration | Gastrointestinal disorders | Treatment With Dasatinib | 1 | 7 | 1 |
1 to 10 of 40Source ClinicalTrials.gov
See all 40 adverse eventsAdverse event totals3
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Treatment With Dasatinib | ||
| Total, other adverse events | Treatment With Dasatinib | 6 | 7 |
| Total, serious adverse events | Treatment With Dasatinib | 3 | 7 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT00858403
GET https://conductscience.org/api/trials/v1/NCT00858403/events?page=2